Cryo-Cell’s Affiliate, Saneron CCEL Therapeutics, Releases Pre-clinical Data Indicating That Cord Blood Stem Cells Slow Progression of ALS
Repeated injections of human umbilical cord blood cells improved motor neuron survival, delayed disease progression and increased lifespan
Oldsmar, FL (PRWEB) March 06, 2012
Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) today announced results of a study published last month in PloS ONE from University of South Florida researchers and colleagues from Saneron CCEL Therapeutics, Inc. and the Ribeirao Preto School of Medicine at the University of Sao Paulo, Brazil. The study showed that repeated, low dose injections of mononuclear cells derived from human umbilical cord blood have been found effective in protecting motor neuron cells, delaying disease progression and increasing lifespan for mice modeling amyotrophic lateral sclerosis, or ALS, also referred to as Lou Gehrig´s disease. Additionally, the researchers found that although the number of grafted cells identified in the spinal cord was low, the treatment was effective, suggesting that various factors secreted by the cells accounted for the therapeutic impact.
Dr. Julie G. Allickson, PhD. Vice President of Laboratory Operations and R&D, stated “This groundbreaking study demonstrates the amazing capacity of cord blood stem cells to potentially treat a devastating neurodegenerative disease through the secretion of trophic factors that resulted in neuroprotection in the ALS mouse model. The data certainly justifies additional pre-clinical investigations using umbilical cord blood stem cells. This source of cells has mainly been used in hematopoietic and immune diseases in more than 25,000 transplants to date.
“Cryo- Cell is excited about the results of the research Saneron CCEL Therapeutics has completed and proud of the progress Saneron has made in the treatment for ALS. The investment community does not appreciate the value of Cryo-Cell´s holdings in Saneron and its world-class research initiatives,” commented David Portnoy, Cryo-Cell´s Chairman and CEO.
“Given the delay between the onset of symptoms and the actual diagnosis of ALS, the data obtained from this study was critically important to show that multiple low-doses of cord blood cells started after the symptomatic disease stage in the ALS mouse model could benefit disease outcomes,” said co-author Nicole Kuzmin-Nichols, President and COO of Saneron CCEL Therapeutics, Inc. “Our continuing studies are aimed at translating the preclinical data into future clinical studies.”
About Cryo-Cell International, Inc.
Cryo-Cell International, Inc. was founded in 1989 and was the world´s first private cord blood bank to separate and store stem cells in 1992. Today, Cryo-Cell has over 240,000 clients worldwide from 87 countries. Cryo-Cell´s mission is to provide our clients with the premier stem cell cryopreservation service and to support the advancement of regenerative medicine.
Cryo-Cell operates in a state-of-the-art Good Manufacturing Practice and Good Tissue Practice (cGMP/cGTP)-compliant facility, is ISO 9001:2008 certified and accredited by the AABB. Cryo-Cell is a publicly traded company. OTC:QB Markets Group Symbol: CCEL. Expectant parents or healthcare professionals may call 1-800-STOR-CELL (1-800-786-7235) or visit http://www.cryo-cell.com.
About Saneron CCEL Therapeutics, Inc.
Saneron CCEL Therapeutics, Inc. is a biotechnology R&D company, focused on neurological and cardiac cell therapy for the early intervention and treatment of several devastating or deadly diseases, which lack adequate treatment options. Saneron, a University of South Florida spin-out company is located at the Tampa Bay Technology Incubator. An affiliate of Cryo-Cell International, Inc., Saneron is committed to providing readily available, noncontroversial stem cells for cellular therapies and has patented and patent-pending technology relating to our platform technology of umbilical cord blood and Sertoli cells.
Statements wherein the terms “believes”, “intends”, “projects”, “anticipates”, “expects”, and similar expressions as used are intended to reflect “forward-looking statements” of the Company. The information contained herein is subject to various risks, uncertainties and other factors that could cause actual results to differ materially from the results anticipated in such forward-looking statements or paragraphs, many of which are outside the control of the Company. These uncertainties and other factors include the success of the Company’s global expansion initiatives and product diversification, the Company’s actual future ownership stake in future therapies emerging from its collaborative research partnerships, the success related to its IP portfolio, the Company’s future competitive position in stem cell innovation, future success of its core business and the competitive impact of public cord blood banking on the Company’s business, the Company’s ability to minimize future costs to the Company related to R&D initiatives and collaborations and the success of such initiatives and collaborations, the success and enforceability of the Company’s Menstrual Stem Cell technology license agreements and Cord Blood Stem Cell Service license agreements and their ability to provide the Company with royalty fees, the ability of Cryology RTS to generate new revenues for the Company, and those risks and uncertainties contained in risk factors described in documents the Company files from time to time with the Securities and Exchange Commission, including the most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and any Current Reports on Form 8-K filed by the Company. The Company disclaims any obligations to subsequently revise any forward-looking statements to reflect events or circumstances after the date of such statements.
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/3/prweb9254979.htm